Treatment and prognostic factors for survival in newly diagnosed multiple myeloma patients with bortezomib and dexamethasone regimen: a single Chinese center retrospective study

References

• San MiguelJFIntroduction to a series of reviews on multiple myelomaBlood2015125203039304025838347
   PubMed Web of Science ®Google Scholar
• SonneveldPGoldschmidtHRosiñolLBortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trialsJ Clin Oncol201331263279328723897961
   PubMed Web of Science ®Google Scholar
• PalumboAFaconTSonneveldPThalidomide for treatment of multiple myeloma: 10 years laterBlood200811183968397718245666
   PubMed Web of Science ®Google Scholar
• BarlogieBEpsteinJSelvanayagamPAlexanianRPlasma cell myeloma—new biological insights and advances in therapyBlood19897348658792465790
   PubMed Web of Science ®Google Scholar
• BarlogieBShaughnessyJTricotGTreatment of multiple myelomaBlood20041031203212969978
   PubMed Web of Science ®Google Scholar
• ChenRChenBZhangXGaoCEfficacy of carfilzomib in the treatment of relapsed and (or) refractory multiple myeloma: a meta-analysis of data from clinical trialsDiscov Med20162212118919927875670
   PubMed Web of Science ®Google Scholar
• ShaughnessyJDJrQuPUsmaniSPharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3Blood2011118133512352421628408
   PubMed Web of Science ®Google Scholar
• DriscollJExpression of E3 ubiquitin ligases in multiple myeloma patients after treatment with the proteasome inhibitor bortezomibCancer Transl Med201515153157
   Google Scholar
• DaiCChenDJiangYHistone H2A and H2B deubiquitinase in developmental disease and cancerCancer Transl Med201515170175
   Google Scholar
• MohtyMMalardFMohtyBSavaniBMoreauPTerposEThe effects of bortezomib on bone disease in patients with multiple myelomaCancer2014120561862324249482
   PubMed Web of Science ®Google Scholar
• AguiarPMde Mendonca LimaTColleoniGWBStorpirtisSEfficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: an overview of systematic reviews with meta-analysesCrit Rev Oncol Hematol201711319521228427509
   PubMed Web of Science ®Google Scholar
• LuJLuJChenWHuoYHuangXHouJClinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysisBlood Cancer J201448e23925127393
   PubMed Web of Science ®Google Scholar
• LiFXuYDengPHeterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myelomaOncotarget20156119434944425831238
   PubMedGoogle Scholar
• GuoHZhouXJiangYBortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: a Chinese experienceAm J Hematol201085749950120575036
   PubMed Web of Science ®Google Scholar
• ChenRChenBGeZEfficacy of carfilzomib in the treatment of relapsed and (or) refractory multiple myeloma: a meta analysis of individual patient data from clinical trialsBlood2016128225675
   Web of Science ®Google Scholar
• ChenRWangYLuanCGaoCZhangXChenBEffect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysisJ Cancer20178101801180828819377
   PubMed Web of Science ®Google Scholar
• KibaTItoTNakashimaTBortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survivalBMC Cancer20141446224952705
   PubMed Web of Science ®Google Scholar
• ChenRATuYCaoYLiuLLiangYBortezomib-dexamethasone or vincristine-doxorubicin-dexamethasone as induction therapy followed by thalidomide as maintenance therapy in untreated multiple myeloma patientsJ Int Med Res20113951975198422118002
   PubMed Web of Science ®Google Scholar
• ZengWMengFLiuZBortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpressionInt J Clin Exp Pathol2014774239424625120804
   PubMed Web of Science ®Google Scholar
• ZwicklHZwickl-TraxlerEPecherstorferMA single-center retrospective analysis of first-line therapy of multiple myeloma with bendamustine-bortezomib-dexamethasoneLeuk Lymphoma20165792065207026901249
   PubMed Web of Science ®Google Scholar
• BianchiGAndersonKCUnderstanding biology to tackle the disease: multiple myeloma from bench to bedside, and backCA Cancer J Clin201464642244425266555
   PubMed Web of Science ®Google Scholar
• BianchiGMunshiNCPathogenesis beyond the cancer clone(s) in multiple myelomaBlood2015125203049305825838343
   PubMed Web of Science ®Google Scholar
• CejalvoMJde la RubiaJClinical treatment of newly diagnosed multiple myelomaExpert Rev Hematol20158559561126327587
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMWAssessment of Proteasome Inhibition for Extending Remissions (APEX) InvestigatorsBortezomib or high-dose dexamethasone for relapsed multiple myelomaN Engl J Med2005352242487249815958804
   PubMed Web of Science ®Google Scholar
• HarousseauJLAttalMLeleuXBortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II studyHaematologica200691111498150517043025
   PubMed Web of Science ®Google Scholar
• SonneveldPSchmidt-WolfIGvan der HoltBBortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trialJ Clin Oncol201230242946295522802322
   PubMed Web of Science ®Google Scholar
• LiuXHeCKMengXBortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trialsOnco Targets Ther201581459146926109870
   PubMed Web of Science ®Google Scholar